Film-coated tablets
Prescription drug

Chlorprothixen Hasco

Composition

Chlorprothixen Hasco, 15 mg: One film-coated tablet contains 15 mg of chlorprothixene hydrochloride (Ambroxoli hydrochloridum).
Excipients of known effect: One film-coated tablet contains 39.27 mg of lactose
monohydrate and sunset yellow, aluminium lake (E 110).
Chlorprothixen Hasco, 50 mg: One film-coated tablet contains 50 mg of chlorprothixene hydrochloride (Ambroxoli hydrochloridum).
Excipients of known effect: One film-coated tablet contains 130.90 mg of lactose
monohydrate and cochineal red, aluminium lake (E 124).

Indications

Treatment of endogenous and organic psychoses with psychomotor agitation and aggression, anxiety and insomnia in neuroses and psychosomatic disorders, alcoholic psychoses.
In surgery – as premedication for sedating the patient and reducing neurovegetative symptoms and for the prevention of post-operative vomiting.

Contraindications

Hypersensitivity to the active substance, thioxanthene derivatives or to any of the excipients indicated in section 6.1. Circulatory collapse, consciousness disorders regardless of aetiology (e.g. alcohol, barbiturate or opioid poisoning), coma. A history of clinically significant cardiovascular disorders (e.g. significant bradycardia (<50 beats/minute), recent acute myocardial infarction, decompensated heart failure, cardiac hypertrophy, heart rhythm disorders treated with class IA and III antiarrhythmic agents), history of tachycardia with torsade de pointes. recent acute myocardial infarction, decompensated heart failure, cardiac hypertrophy, heart rhythm disorders treated with class IA and III antiarrhythmic agents), history of tachycardia with torsade de pointes. Congenital long QT syndrome or diagnosed acquired long QT (QTc above 450 ms in men and above 470 ms in women). Use of drugs that prolong QT (see section 4.5). Diagnosed , uncompensated hypokalaemia and diagnosed, uncompensated magnesium deficiency.

This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.

Drug information

phone: (+48) 22 742 00 22
informacjaoleku@hasco-lek.pl
Film-coated tablets
Prescription drug

Chlorprothixen Hasco

Drug information

phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl

Composition

Chlorprothixen Hasco, 15 mg: One film-coated tablet contains 15 mg of chlorprothixene hydrochloride (Ambroxoli hydrochloridum).
Excipients of known effect: One film-coated tablet contains 39.27 mg of lactose
monohydrate and sunset yellow, aluminium lake (E 110).
Chlorprothixen Hasco, 50 mg: One film-coated tablet contains 50 mg of chlorprothixene hydrochloride (Ambroxoli hydrochloridum).
Excipients of known effect: One film-coated tablet contains 130.90 mg of lactose
monohydrate and cochineal red, aluminium lake (E 124).

Indications

Treatment of endogenous and organic psychoses with psychomotor agitation and aggression, anxiety and insomnia in neuroses and psychosomatic disorders, alcoholic psychoses.
In surgery – as premedication for sedating the patient and reducing neurovegetative symptoms and for the prevention of post-operative vomiting.

Contraindications

Hypersensitivity to the active substance, thioxanthene derivatives or to any of the excipients indicated in section 6.1. Circulatory collapse, consciousness disorders regardless of aetiology (e.g. alcohol, barbiturate or opioid poisoning), coma. A history of clinically significant cardiovascular disorders (e.g. significant bradycardia (<50 beats/minute), recent acute myocardial infarction, decompensated heart failure, cardiac hypertrophy, heart rhythm disorders treated with class IA and III antiarrhythmic agents), history of tachycardia with torsade de pointes. recent acute myocardial infarction, decompensated heart failure, cardiac hypertrophy, heart rhythm disorders treated with class IA and III antiarrhythmic agents), history of tachycardia with torsade de pointes. Congenital long QT syndrome or diagnosed acquired long QT (QTc above 450 ms in men and above 470 ms in women). Use of drugs that prolong QT (see section 4.5). Diagnosed , uncompensated hypokalaemia and diagnosed, uncompensated magnesium deficiency.